scholarly journals Long-Term Follow-up of a Case with Proprotein Convertase 1/3 Deficiency: Transient Diabetes Mellitus with Intervening Diabetic Ketoacidosis During Growth Hormone Therapy

2017 ◽  
Vol 9 (3) ◽  
pp. 283-287 ◽  
Author(s):  
E. Nazlı Gönç ◽  
Alev Özön ◽  
Ayfer Alikaşifoğlu ◽  
Nurgün Kandemir
Keyword(s):  
Diabetes Mellitus ◽  
Growth Hormone ◽  
Hormone Therapy ◽  
Diabetic Ketoacidosis ◽  
Growth Hormone Therapy ◽  
Proprotein Convertase ◽  
Long Term Follow Up

scholarly journals Uterine size in women with Turner syndrome after induction of puberty with estrogens and long-term growth hormone therapy: results of the German IGLU Follow-up Study 2001

2005 ◽  
Vol 20 (5) ◽  
pp. 1418-1421 ◽  
Author(s):  
Helmuth G. Doerr ◽  
Markus Bettendorf ◽  
Berthold P. Hauffa ◽  
Otto Mehls ◽  
Carl-Joachim Partsch ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Turner Syndrome ◽  
Growth Hormone Therapy ◽  
Follow Up Study

scholarly journals Impact of Coronary Artery Disease and Diabetes Mellitus on the Long-Term Follow-Up in Patients after Retrograde Recanalization of the Femoropopliteal Arterial Region

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Joanna Wojtasik-Bakalarz ◽  
Zoltan Ruzsa ◽  
Tomasz Rakowski ◽  
Andreas Nyerges ◽  
Krzysztof Bartuś ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Risk Of Death ◽  
Significant Difference ◽  
Long Term Follow Up ◽  
Artery Disease ◽  
The Impact

The most relevant comorbidities in patients with peripheral artery disease (PAD) are coronary artery disease (CAD) and diabetes mellitus (DM). However, data of long-term follow-up of patients with chronic total occlusion (CTO) are scarce. The aim of the study was to assess the impact of CAD and DM on long-term follow-up patients after superficial femoral artery (SFA) CTO retrograde recanalization. In this study, eighty-six patients with PAD with diagnosed CTO in the femoropopliteal region and at least one unsuccessful attempt of antegrade recanalization were enrolled in 2 clinical centers. Mean time of follow-up in all patients was 47.5 months (±40 months). Patients were divided into two groups depending on the presence of CAD (CAD group: n=45 vs. non-CAD group: n=41) and DM (DM group: n=50 vs. non-DM group: n=36). In long-term follow-up, major adverse peripheral events (MAPE) occurred in 66.6% of patients with CAD vs. 36.5% of patients without CAD and in 50% of patients with DM vs. 55% of non-DM subjects. There were no statistical differences in peripheral endpoints in both groups. However, there was a statistically significant difference in all-cause mortality: in the DM group, there were 6 deaths (12%) (P value = 0.038). To conclude, patients after retrograde recanalization, with coexisting CTO and DM, are at higher risk of death in long-term follow-up.

Sign in / Sign up

Export Citation Format

Share Document